Mylotarg Related Clinical Trials
Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk [Recruiting]
Study Evaluating the Effect of Corticosteroids on Mylotarg® Infusion-Related Adverse Events in Patients With Leukemia [Completed]
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS) [Recruiting]
Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin [Recruiting]
Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia [Recruiting]
Azacitidine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant [Recruiting]
Azacitidine and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [Recruiting]
Study Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care [Completed]
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS [Active, not recruiting]
Cytarabine, Fludarabine, and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome [Recruiting]
Bendamustine Hydrochloride and Idarubicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia or Myelodysplastic Syndrome [Recruiting]
A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old [Recruiting]
Nonmyeloablative Preparative Regimen Using Mylotarg for Patients With High Risk Acute Myeloid Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myeloid Leukemia (CML) and Myelodysplastic Syndrome (MDS) [Terminated]
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS. [Completed]
A Trial of the Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) [Recruiting]
Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Active, not recruiting]
Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation [Recruiting]
Vorinostat, Gemtuzumab Ozogamicin, and Azacitidine in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia [Recruiting]
Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia [Completed]
Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia [Active, not recruiting]
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia [Active, not recruiting]
Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML [Recruiting]
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia [Active, not recruiting]
NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia [Recruiting]
Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia [Not yet recruiting]
Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML) [Recruiting]
Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation [Recruiting]
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia [Completed]
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [Recruiting]
Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia [Recruiting]
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant [Completed]
Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia After Stem Cell Transplantation [Completed]
Fludarabine, Cytarabine, Filgrastim and Idarubicin in Core Binding Factor (CBF) Leukemias [Recruiting]
LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML) [Recruiting]
Vorinostat and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [Recruiting]
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes [Recruiting]
Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM) [Active, not recruiting]
Allogeneic Stem Cell Transplantation Followed By Targeted Immune Therapy In Average Risk Leukemia [Recruiting]
Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia [Completed]
Gemtuzumab Ozogamicin, Fludarabine, and Total-Body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome [Active, not recruiting]
Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia [Active, not recruiting]
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy [Completed]
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome [Active, not recruiting]
CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse [Active, not recruiting]
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse [Active, not recruiting]
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes [Recruiting]
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia [Active, not recruiting]
Combination Chemotherapy With or Without Monoclonal Antibody Therapy Followed by Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia [Recruiting]
SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717) [Recruiting]
Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes [Active, not recruiting]
All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab [Recruiting]
Gemtuzumab in Treating Patients With Myelodysplastic Syndrome [Active, not recruiting]
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes [Completed]
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) [Recruiting]
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia [Completed]
Autologous Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia After Relapse With Idarubicin and Busulfan Conditioning [Recruiting]
Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia [Recruiting]
|
